Happy Holidays and a Happy New Year from all at Median

Happy Holidays and a Happy New Year from all at Median

CEO’s message


Fredrik Brag talks about how we’re looking to change the game. To transform the landscape in which we work and create a new world of possibilities for biopharma companies and healthcare professionals alike.

Read more

The Imaging Phenomics Company®

Median Technologies is the Imaging Phenomics Company®. Learn about our MediScan® portfolio for Patient Care, our Lesion Management Solution (LMS) technology and iBiopsy®, our Imaging Biomarker Phenotyping System.

Watch

News

13 December 2018

Median Technologies appoints Dr. Nozha Boujemaa as Chief Science and Innovation Officer

Dr. Nozha Boujemaa will oversee the company scientific vision as well as strategies for innovation, development and academic and industrial partnerships for iBiopsy®, the Median Technologies Imaging Phenomics platform.

11 October 2018

Median Technologies reports its financial results for H1 2018 and announces its strategic shift in focus to its imaging phenomics platform iBiopsy®

Median Technologies reports its financial results for H1 2018 and announces its strategic shift in focus to its imaging phenomics platform iBiopsy®
H1 2018 revenue: €3.4 million
Order backlog as of June 30, 2018: €21.4 million
Refocusing research and development activities on iBiopsy®

26 July 2018

Financial Communications Schedule for the Second Half of 2018

Median Technologies, The Imaging Phenomics Company®, announces the publication date for its half year results 2018.

12 July 2018

Median Technologies receives the Forbes 2018 Futur40 award and special recognition prize for the “Health-Life Sciences” company category

Median Technologies, The Imaging Phenomics Company®, announces that on July 11, it received the 2018 Futur40 award and special recognition prize in the category “Health-Life Sciences”. These prizes are awarded by Forbes, PMEFinance-EuropeEntrepreneurs and their partners Euronext, MorningStar, RSM, F2iC and Paris Europlace to distinguish French champions of growth.

10 July 2018

Half-year liquidity contract statement signed between Median Technologies and AUREL BGC

Half-year liquidity contract statement signed between Median Technologies and AUREL BGC at June 30, 2018.

1/5

Opinion

8 August 2018
New White Paper – Innovations in Cancer Screening

New White Paper – Innovations in Cancer Screening

New White Paper – Innovations in Cancer Screening There has been great progress in the diagnosis and treatment of cancer in recent years,…

10 July 2018
Demystifying How Images Are Managed

Demystifying How Images Are Managed

Demystifying How Images Are Managed Between February 2017 and January 2018, ~41.4 million diagnostic imaging tests were performed in England[i]. That so many…

18 June 2018
ASCO 2018: Headlines and Highlights

ASCO 2018: Headlines and Highlights

ASCO 2018: Headlines and Highlights All eyes were on the American Society of Clinical Oncology (ASCO) Annual conference last week in Chicago watching…

15 May 2018
Immunotherapy Update: Recent Advances in CAR T-cell Therapy

Immunotherapy Update: Recent Advances in CAR T-cell Therapy

Immunotherapy Update: Recent Advances in CAR T-cell Therapy As a measure of its promise, chimeric antigen receptor (CAR) T-cell therapy – where patients’…

14 March 2018
Industry Trends:  AI Revolutionizes Imaging Analysis

Industry Trends: AI Revolutionizes Imaging Analysis

Industry Trends:  AI Revolutionizes Imaging Analysis The radiology industry is embracing artificial intelligence (AI) to enhance image analysis, and it’s having a profound impact…

1/5
Imaging for patient care

Identifying treatments that work

Imaging biomarkers provide a unique insight into treatment progress at every stage of a disease. In cancer for instance, comprehensive quantitative information plays an invaluable role in defining, tracking and measuring treatment outcomes. Providing clear evidence of what works and what doesn’t.

Read more

Imaging for clinical trials

Advancing treatments of the future

Working with biopharmaceutical companies, and leading medical centers around the world, the team at Median enable researchers to identify disease fingerprints from medical images. We’re helping paving the way for new personalized and innovative medicines, more accurate and predictable diagnoses and better treatments

Read more

Ibiopsy®

Powering the phenomics revolution

We’re changing the game; transforming the landscape. We’re capturing the power of big data and unique biomarker imaging technology to create a new world of possibilities for biopharma and healthcare professionals alike. Our iBiopsy® platform opens up the field of phenomics, driving the science of precision medicine.

Read more

Investors

Delivering value

Our technology and expertise is creating a new world of possibilities for biopharmaceutical and healthcare professionals around the world. By successfully helping improve the lives of millions, we are also delivering value for our investors and partners.

Read more

Stock Market Data

TICKER: ALMDT ISIN: FR0011049824
Get in touch
Europe
United States
China

china

12/F Platinum Tower
233 Tai Cang Road
Shanghai 200020
China

europe

Median Technologies
Les Deux Arcs, Bât B
1800, route des Crêtes
06560 Valbonne
France

United States

Legal address
Median Technologies Inc
C/O Pramex International
1251 Avenue of the Americas
3rd Floor
New York NY 10020

US offices

Median Technologies Inc
300 TradeCenter
Suite 5610
Woburn MA 01801

Get in touch

Get in touch





Jobs at Median

Cookies help us deliver our services. By using our services, you agree to our use of cookies.